Aventis Pharma Deutschland, Gmbh

Hoechst Aktiengesellschaft

Sanofi-a Ventis Deutschland Gmbh

Martin Knauf

Laszlo Vertesy

Joachim Wink

Luigi Toti

Astrid Markus-Erb

Jozsef Aszodi

Wilhelm Stahl

Dieter Isert

Gunther J Riess

Dominique Le Beller

Cordula Hopmann

Matthias Schiell

Klaus Ehrlich

Mark Brönstrup

Marie-Cecile Raynal-Wetzel

Florence Fassy

Elaine A Powers

Francis P Barbone

Elizabeth A Cashman

The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.

Hydroxyphenylundecane, a process for their production and their use

The present invention relates to compounds of the formula (I)which are formed by the microorganism ST 003236 (DSM 14476) during fermentation, to a process for preparing and derivatizing them, to a pharmaceutical which comprises a compound of the formula (I) and to the use thereof for producing a pharmaceutical.

Gabusectin derivatives, processes for preparing them and their use

Coniosetin and derivatives thereof, process for the preparation and the use thereof

Pluraflavins and derivatives thereof, process for their preparation and use thereof

This invention relates to the antibiotic feglymycin, as well as processes for its preparation and use. Feglymycin is represented by the structural formula (SEQ. ID. NO. 1) ##STR1##

Methods of treatment with novel antibiotic feglymycin

This invention relates to the antibiotic feglymycin, as well as processes for its preparation and use. Feglymycin is represented by the structural formula (SEQ ID NO:1): ##STR1##

Antibiotic, feglymycin, processes for its preparation and its use

Growing community of inventors

Rapperswil, Switzerland

Martin Knauf